Cancer Biomarkers Market\nThe Global Cancer Biomarkers Market reached USD 13.2 billion in 2022 and is expected to witness lucrative growth by reaching up to USD 32.5 billion by 2031. The global cancer biomarker market is expected to exhibit a CAGR of 12.3% during the forecast period (2024-2031). Cancer Biomarkers Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Innovations in AI-driven biomarker analysis, multi-omics approaches, and targeted therapies are shaping market dynamics. The Cancer Biomarkers Market focuses on biological molecules used for cancer detection, diagnosis, prognosis, and treatment monitoring. These include genetic, protein, and metabolic markers. Growth is driven by rising cancer prevalence, advancements in precision medicine, and increasing adoption of liquid biopsy techniques. The report lists key players in the market such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Enzo Biochem, Inc., Merck Millipore, Micron Technology, among others. The report discusses recent industry developments like the partnership between Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI) to study the link between molecular cancer biomarkers and patient response to immunotherapy, and the partnership between OncoDNA and Eli Lilly Italia to improve biomarker testing access for thyroid cancer patients in Italy. The report covers segments by cancer indication, biomarker type, profiling technology, and end user. Regional analysis includes North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. The report provides a comprehensive analysis of the demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis, and forecast in the global market. It also includes top-down and bottom-up approaches for regional analysis, and a Porter's five forces model analysis. The report aims to provide actionable intelligence to empower businesses to make informed decisions and stay ahead of the competition.

Cancer Biomarkers Market: Emerging Trends, Growth Drivers &

The Global Cancer Biomarkers Market is projected to reach USD 32.5 billion by 2031, with a CAGR of 12.3% from 2024 to 2031. This growth is driven by advancements in AI-driven biomarker analysis, multi-omics approaches, and targeted therapies. The market focuses on biological molecules for cancer detection, diagnosis, prognosis, and treatment monitoring, including genetic, protein, and metabolic markers. Key players include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, Enzo Biochem, Inc., Merck Millipore, and Micron Technology. Recent industry developments include partnerships between Guardant Health, Inc. and the Parker Institute for Cancer Immunotherapy (PICI), and OncoDNA and Eli Lilly Italia to enhance biomarker testing access for thyroid cancer patients in Italy.